Evidence map›Paper›PMID 38139172›Full record

ArticleInternational journal of molecular sciences2023

Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.

Alexey I Kalinkin, Vladimir O Sigin, Ekaterina B Kuznetsova, Ekaterina O Ignatova, Ilya I Vinogradov, Maxim I Vinogradov, Igor Y Vinogradov, Dmitry V Zaletaev, Marina V Nemtsova, Sergey I Kutsev and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Multi-Omics Analysis IdentifiedInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Alexey I KalinkinResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0001-9215-4581
Vladimir O SiginResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Ekaterina B KuznetsovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0001-5825-0430
Ekaterina O IgnatovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-8114-7885
Ilya I VinogradovRegional Clinical Oncology Dispensary, 390011 Ryazan, Russia.
Maxim I VinogradovDepartment of Histology, Pathological Anatomy and Medical Genetics, Ryazan State Medical University, 390026 Ryazan, Russia.
Igor Y VinogradovDepartment of Histology, Pathological Anatomy and Medical Genetics, Ryazan State Medical University, 390026 Ryazan, Russia.
Dmitry V ZaletaevResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-9323-2673
Marina V NemtsovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Sergey I KutsevResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Alexander S TanasResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-2177-6743
Vladimir V StrelnikovResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0001-9283-902X
Research Centre for Medical Genetics · RURyazan State Medical University named after Academician I.P. Pavlov · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype, with a poor survival rate compared to others subtypes. For a long time, chemotherapy was the only systemic treatment for TNBC, and the identification of actionable molecular targets might ultimately improve the prognosis for TNBC patients. We performed a genome-wide analysis of DNA methylation at CpG islands on a collection of one hundred ten breast carcinoma samples and six normal breast tissue samples using reduced representation bisulfite sequencing with the XmaI restriction enzyme (XmaI-RRBS) and identified a subset of TNBC samples with significant hypomethylation at the

Indexed as

Triple Negative Breast NeoplasmsCell Line, TumorEpigenomicsHumansReceptors, LeukotrieneSulfiteshydrogen sulfiteReceptors, LeukotrieneSulfitesbreast cancerDNA methylationleukotriene receptorsXmaI-RRBS

Identifiers

PMID38139172
PMCPMC10743620
OpenAlexW4389565859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.